Results indicate that full-pool retrieval, hard-confounder discrimination, and observable evidence access capture complementary aspects of model behavior, which provides a foundation for more transparent and evidence-aware evaluation of phenotype-driven diagnostic systems.
Abstract
Phenotype-driven diagnostic benchmarks usually report the rank of the reference disease, but they rarely reveal which plausible alternatives are ranked above it or what evidence a tool-using model examines before making its decision. We introduce GraphRareBench, a provenance-preserving benchmark containing 2,365 ontology-derived cases and 18,093 target-confounder pairs. Each case includes a coarsened HPO query, a fixed candidate pool, graph-defined hard confounders, and source-linked evidence records. On the 237-case gene-component-disjoint test split, supervised rankers using a shared 21-feature interface achieved MRRs ranging from 0.640 to 0.740 and case-averaged target-over-confounder accuracies ranging from 0.898 to 0.916. Agents instantiated with Agents-A1 and DeepSeek-V4-Flash achieved MRRs of 0.746 and 0.718, respectively. Their paired MRR difference was not statistically significant, whereas their target-evidence coverage differed by 0.561. Together with the observation that 22.1% to 43.7% of selected Hit@10 successes still ranked at least one graph-defined hard confounder above the target, these results indicate that full-pool retrieval, hard-confounder discrimination, and observable evidence access capture complementary aspects of model behavior. GraphRareBench therefore provides a foundation for more transparent and evidence-aware evaluation of phenotype-driven diagnostic systems. Code and data are available at https://github.com/GUI0609/GraphRareBench.
Ontology rankers remain useful for rare-disease diagnosis because each candidate can be traced to matched patient phenotypes. Large language models (LLMs) can generate differential diagnoses from the same patient description, but their predictions lack an equally clear evidence trail. Rather than asking which system sh...
Zhao-Yang Jiang, Zhizhong Fu, Yunsoo Kim et al.· 0 citations
Benchmarks for rare-disease gene prioritisation are assembled from published clinical cases. Those cases often come from the same publications used to build knowledge-base (“curated”) tools, so a curated tool can be scored on its own source literature. This resource makes that circularity measurable. We release a strat...
Johanna Angulo, Héctor Espinós-Morató, Víctor Yeste· bioRxiv· 0 citations
OncoRAG enables accurate clinical phenotyping from multilingual oncology notes using a locally deployable mid-size model, without model weight fine-tuning or external data sharing.
P. Salome, M. Knoll, David Walz et al.· npj Digital Medicine· 0 citations
Results indicate that structured medical knowledge can turn a compact model into a competitive diagnostic ranker across heterogeneous long-tail settings in clinical practice.
Bo Zhang, Yu-Chen Wang, Dong-Bai Li et al.· 0 citations
Biomedical graph-learning results are difficult to compare when source versions, identifier rules, data splits, structural features, and sampled-nonedge contracts are incompletely documented.
We developed BioGraphBench-PPI as an audit-first benchmark for protein-protein interaction (PPI) link prediction usin...
A. Cabrera-Andrade, Jorge Robalino-Díaz, I. Dueñas-Espín et al.· Frontiers in Bioinformatics· 0 citations
Key results support a general conclusion: feature-graph guidance can improve small-sample multivariate quality assessment when the supplied structure is outcome-relevant, but graph relevance must be tested rather than assumed.
Q. Li, K. Yu· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.